Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02172950 · ClinicalTrials.gov registry record · Phase 3
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 246
- Enrollment target
NCT02172950 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 246 participants.
The verdict
NCT02172950, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 246 participants
- Enrollment target
Study Summary
This multicenter, open-label, phase 3 extension study will investigate the safety and efficacy of rVIII-SingleChain for prophylaxis and on-demand treatment of bleeding episodes in at least 200 previously treated patients (PTPs) with severe congenital hemophilia A and previous exposure to FVIII products who achieve at least 100 exposure days (EDs) to rVIII-SingleChain in this study, as well as in previously untreated patients (PUPs) with no previous exposure to any FVIII product who achieve at least 50 EDs to rVIII-SingleChain in this study. A substudy (open to both PTPs and PUPs) will investigate the use of rVIII-SingleChain in surgery. A substudy (open to PUPs who develop an inhibitor to rVIII-SingleChain) will investigate the use of rVIII-SingleChain in immune tolerance induction (ITI) therapy.
Interventions
- BIOLOGICAL rVIII-SingleChain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2021-01-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02172950
The ClinicalTrials.gov registry entry for NCT02172950 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rVIII-SingleChain is the first listed.
NCT02172950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02172950 about?
NCT02172950 is a clinical study titled "An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A". This multicenter, open-label, phase 3 extension study will investigate the safety and efficacy of rVIII-SingleChain for prophylaxis and on-demand treatment of bleeding episodes in at least 200 previously treated patients (PTPs) with severe congenital hemophilia A and previous exposure to FVIII produ...
What is the current status of trial NCT02172950?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 246 participants. The study started on 2014-10-13. Estimated completion is 2021-01-19.
What interventions are being tested in trial NCT02172950?
The interventions under investigation include: rVIII-SingleChain (BIOLOGICAL).
Who is sponsoring clinical trial NCT02172950?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.